世界卫生组织药品安全监测工作概况及思考

doi:10.19803/j.1672-8629.2021.01.08

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (1): 43-46.
DOI: 10.19803/j.1672-8629.2021.01.08

世界卫生组织药品安全监测工作概况及思考

樊蓉, 董铎^*

国家药品监督管理局药品评价中心, 北京 100022

收稿日期:2020-04-15 修回日期:2021-01-18 出版日期:2021-01-15 发布日期:2021-01-18
通讯作者: ^*董铎,女,博士,主任药师,药品不良反应监测。E-mail:dongduo@cdr-adr.org.cn
作者简介:樊蓉,女,硕士,主管药师,药品不良反应监测。
基金资助:
国家科技重大专项项目(2017ZX09101001-001-003):药品再评价政策法规及实施策略研究

Overview and Thoughts on WHO International Drug Monitoring

FAN Rong, DONG Duo

Center for Drug Reevaluation,NMPA,Beijing 100022,China

Received:2020-04-15 Revised:2021-01-18 Online:2021-01-15 Published:2021-01-18

摘要/Abstract

摘要： 回顾世界卫生组织国际安全监测项目发展历程及其合作中心基本情况,介绍乌普萨拉监测中心在数据管理和技术支持、科学研究、世界卫生组织药物词典等方面的工作,为深入了解国际药品安全监测组织机构及其职责、进一步开展相关国际合作提供参考。

关键词: 世界卫生组织国际药物监测项目, 药品安全监测, 乌普萨拉监测中心, 世界卫生组织合作中心, 药品不良反应

Abstract: This article was intended to review the history of the World Health Organization (WHO) Programme for International Drug Monitoring and the WHO Collaborating Centres,and to introduce the work of Uppsala Monitoring Center (UMC),including data management and technical support,scientific research,and WHO Drug Global so as to provide reference for future cooperation.

Key words: WHO programme for international drug monitoring, drug safety monitoring, Uppsala monitoring center, WHO collaborating centres, adverse drug reaction

中图分类号:

樊蓉, 董铎. 世界卫生组织药品安全监测工作概况及思考[J]. 中国药物警戒, 2021, 18(1): 43-46.

FAN Rong, DONG Duo. Overview and Thoughts on WHO International Drug Monitoring[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 43-46.

参考文献

[1] WHO Basic documents:forty-ninth edition (including amendments adopted up to 31 May 2019)[R].to 31 May 2019)[R].Geneva:World Health Organization,2020.
[2] UMC.The story of UMC and the WHO programme[EB/OL].(2020-01-16)[2020-08-01].https://www.who-umc.org/global-pharmacovigilance/who-programme/the-story-of-umc-and-the-who-programme/.
[3] UMC.Members of the WHO Programme for International Drug Monitoring[EB/OL].(2020-06-22)[2020-08-01].https://www.who-umc.org/research-scientific-development/collaborations/previous-collaborations/.
[4] Yang Y.Research on the implementation of pharmacovigilance system in drug administration law and the application of ICH e2 guideline[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(2):65-71.
[5] WHO.Guide for WHO collaborating centres[EB/OL].(2018-01-01)[2020-08-01].http://www.who.int/collaborating centres/information/en/.
[6] WHO.WHO collaborating centres database &portal[DB/OL].(2020-08-01)[2020-08-01].http://apps.who.int/whocc/.
[7] WEB-RADR.First innovative medicines initiative WEB-RADR workshop:mobile technologies and social media as new tools in pharmacovigilance[EB/OL].(2015-01-05)[2020-08-01].https://web-radr.eu/2015/01/05/first-innovative-medicines-initiative-web-radr-workshop-mobile-technologies-and-social-media-as-new-tools-in-pharmacovigilance/.
[8] George Hripcsak,Jon D Duke,Nigam H Shah,et al.Observational health data sciences and informatics (OHDSI):opportunities for observational researchers[J].Stud Health Technol Inform,2015(216):574-578.
[9] UMC.Previous collaborations[EB/OL].(2017-09-26)[2020-08-01].https://www.who-umc.org/research-scientific-development/collab-orations/previous-collaborations/.
[10] UMC.WHODrug global Chinese[EB/OL].(2019-10-10)[2020-08-01].https://www.who-umc.org/whodrug/whodrug-portfolio/whodrug-global/whodrug-global-chinese/.
[11] UMC.What is WHO-ART?[EB/OL].(2017-12-14)[2020-08-01].https://www.who-umc.org/vigibase/services/learn-more-about-who-art/.
[12] UMC.International pharmacovigilance training course:Join us in Uppsala,Sweden,for our long-established annual pharmacovigilance course.[EB/OL].(2020-03-04)[2020-08-01].https://www.who-umc.org/education-training/educationtraining/international-pharma-covigilance-training-course/.
[13] UMC.ISoP-UMC training:The International Society of Pharmac-ovigilance (ISoP) andUMC collaborate in educational initiatives to strengthen pharmacovigilance in Asia and in Latin America.[EB/OL].(2020-01-07)[2020-08-01].https://www.who-umc.org/education-training/education-training/isop-umc-training/
[14] NMPA.The State Food and Drug Administration became a member of the International Technical Coordination Committee for Registration of Human Drugs[EB/OL].(2017-06)[2020-08-01].http://www.nmpa.gov.cn/WS04/CL2097/318606.html.
[15] NMPA.China's National Medical Products Administration was elected as a member of the Management Committee of the International Human Drug Registration Technical Coordination Committee[EB/OL].(2018-06)[2020-08-01].http://www.nmpa.gov.cn/WS04/CL2056/228304.html.
[16] Dong D,Liu W,Fan Y,et al.Brief analysis and enlightenment on 2018 annual report of eudravigilance[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2020,17(1):26-30.

世界卫生组织药品安全监测工作概况及思考

Overview and Thoughts on WHO International Drug Monitoring

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.